RADIOLABELING OF MONOCLONAL-ANTIBODY B43.13 WITH RE-188 FOR IMMUNORADIOTHERAPY

In this study we report a novel method for direct radiolabeling of mon oclonal antibody B43.13 (MAb-B43.13) with Re-188 and have evaluated th e product's radiochemical, biochemical, immunochemical and selected bi ological properties. Re-188-MAb-B43.13 was readily prepared by the add ition of generator produced perrhenate to a preformulated antibody via l after an optimal amount of supplemental stannous ion, in the form of stannous tartrate, was added. The final radiolabeled product retained its biochemical purity (as determined by size-exclusion HPLC and R/NR -SDS-PAGE), its immunoreactivity (as determined by immunoassay) and pr esented with a typical stability (in the presence of serum and cystein e) and biodistribution (in tumored mice) profile. The evaluation of th e product for immunoradiotherapy of ovarian cancer in a clinical setti ng requires further studies. (C) 1997 Elsevier Science Ltd.